Edesa Biotech (NASDAQ:EDSA) | Finanzwire

Basculer en Français

8296	Companies
114902	Keywords
55332	Articles
62460	Press releases

Home
Companies
Edesa Biotech

BRIEF

published on 06/24/2024 at 14:25, 4 months 26 days ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Clinical Trial Edesa Biotech ARDS BARDA Paridiprubart
PRESS RELEASE

published on 06/24/2024 at 14:20, 4 months 26 days ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
Edesa Biotech's paridiprubart selected for BARDA-funded Phase 2 trial to evaluate treatment for ARDS in hospitalized patients. Study to focus on threat-agnostic host-directed therapeutics

Edesa Biotech ARDS Phase 2 Trial Paridiprubart BARDA-funded
BRIEF

published on 05/10/2024 at 22:20, 6 months 10 days ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Financial Performance Edesa Biotech Clinical Studies Fiscal Quarterly Results ARDS Treatment
PRESS RELEASE

published on 05/10/2024 at 22:15, 6 months 10 days ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
Edesa Biotech, Inc. reported financial results for the three and six months ended March 31, 2024, focusing on its Phase 3 ARDS study, EB05 drug candidate, and strategic plans for respiratory technology and dermatology. The company showcased operational efficiency and prudent capital management

Financial Results Edesa Biotech Inc Phase 3 ARDS Study EB05 Drug Candidate Respiratory Technology
BRIEF

published on 04/11/2024 at 15:05, 7 months 9 days ago

Edesa Biotech Confirms Participation in 2024 Bloom Burton Healthcare Investor Conference

Immuno-inflammatory Diseases Clinical Trials Biopharmaceutical Edesa Biotech Healthcare Conference
PRESS RELEASE

published on 04/11/2024 at 15:00, 7 months 9 days ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech, Inc. (NASDAQ:EDSA) to participate in Bloom Burton & Co. Healthcare Investor Conference, with CEO Par Nijhawan presenting. Company focuses on host-directed therapeutics for immuno-inflammatory diseases

Immuno-inflammatory Diseases EB05 Edesa Biotech NASDAQ:EDSA Bloom Burton & Co. Healthcare Investor Conference
BRIEF

published on 04/02/2024 at 15:05, 7 months 18 days ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Investor Conferences Clinical Trials Biopharmaceuticals Edesa Biotech Immunotherapy
PRESS RELEASE

published on 04/02/2024 at 15:00, 7 months 18 days ago

Edesa Biotech to Participate in Upcoming Investor Conferences
Edesa Biotech, Inc. announces participation in upcoming investor conferences in Toronto, London, and New York to present innovative treatments for immuno-inflammatory diseases

Clinical-stage Biopharmaceutical Company Immuno-inflammatory Diseases Investor Conferences Edesa Biotech Inc. Therapeutics
BRIEF

published on 03/21/2024 at 21:35, 7 months 30 days ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Fireside Chat Edesa Biotech Inflammatory Diseases Autoimmune Conference Clinical-Stage Biopharmaceutical
PRESS RELEASE

published on 03/21/2024 at 21:30, 7 months 30 days ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
Edesa Biotech to participate in H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference. Fireside Chat with CEO Par Nijhawan, MD and analyst scheduled for March 28, 2024

Fireside Chat Edesa Biotech H.C. Wainwright Autoimmune & Inflammatory Disease Par Nijhawan

1 2 ... 4

Accesswire

Published on 11/21/2024 at 13:30, 12 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 12 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 42 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 42 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 42 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 27 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 7 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 27 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 35 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 42 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 44 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 22 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 57 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 57 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE